Medinet Co Ltd
TSE:2370

Watchlist Manager
Medinet Co Ltd Logo
Medinet Co Ltd
TSE:2370
Watchlist
Price: 40 JPY Market Closed
Market Cap: 10.6B JPY
Have any thoughts about
Medinet Co Ltd?
Write Note

Medinet Co Ltd
Gain/Loss on Disposition of Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Medinet Co Ltd
Gain/Loss on Disposition of Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gain/Loss on Disposition of Assets CAGR 3Y CAGR 5Y CAGR 10Y
Medinet Co Ltd
TSE:2370
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CMIC Holdings Co Ltd
TSE:2309
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Chiome Bioscience Inc
TSE:4583
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Precision System Science Co Ltd
TSE:7707
Gain/Loss on Disposition of Assets
-ÂĄ2.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CellSource Co Ltd
TSE:4880
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WDB coco Co Ltd
TSE:7079
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Medinet Co Ltd
Glance View

Market Cap
10.3B JPY
Industry
Life Sciences Tools & Services

MEDINET Co., Ltd. engages in cell processing business. The company is headquartered in Ota-Ku, Tokyo-To and currently employs 83 full-time employees. The company went IPO on 2003-10-08. The company operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. The company also provides comprehensive support services for immune cell therapy.

Intrinsic Value
7.7 JPY
Overvaluation 81%
Intrinsic Value
Price

See Also

Back to Top